APX 004
Alternative Names: APX004; DYW 101Latest Information Update: 24 Aug 2023
Price :
$50 *
At a glance
- Originator Epitomics
- Developer Gansu Duyiwei Biological Pharmaceutical; Pyxis Oncology
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 23 Aug 2023 Apexigen has been acquired and merged into Pyxis Oncology
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in China (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)